A

Alaunos Therapeutics Inc
NASDAQ:TCRT

Watchlist Manager
Alaunos Therapeutics Inc
NASDAQ:TCRT
Watchlist
Price: 3.24 USD -0.61% Market Closed
Market Cap: 6.4m USD

Alaunos Therapeutics Inc
Investor Relations

Alaunos Therapeutics, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is focused on discovering, developing, and commercializing immuno-oncology platforms. The firm is engaged in developing technologies that utilize the immune system by employing innovative cell engineering to deliver cell therapies for the treatment of multiple cancer types. The company is focused on developing T-cell receptor (TCR), T cell therapies to target neoantigens in solid tumors (TCR-T). The firm's platform Sleeping Beauty is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that engineers T cells outside of the body for subsequent infusion. The company targets tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR, which are prevalent in gastrointestinal, lung, and gynecological cancers. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Show more
Loading

Earnings Calls

2023 Q1
May 10, 2023
Show Transcript
Previous
Next
Alaunos Therapeutics Reports Progress and Financials for Q1 2023
2023 Q1
May 10, 2023

In the first quarter of 2023, Alaunos Therapeutics reported a net loss of approximately $10 million, slightly higher than the previous year. Its operating cash burn increased to about $9.4 million as the company accelerated patient enrollment in its TCR-T library Phase 1/2 trial. By the end of the year, they expect to treat between 9 to 12 patients. Alaunos aims to expand its TCR library to 15 TCRs and anticipates a significant interim readout of new clinical data in Q3 2023. Additionally, successful amendments to their IND have streamlined processes, while eliminating prior financial obligations enhances their balance sheet【4:1†source】.

Management

Mr. Dale Curtis Hogue Jr.
Interim CEO & Director
No Bio Available
Ms. Melinda Lackey
Senior VP of Legal, Administration & Secretary
No Bio Available
Mr. Michael Wong
Vice President of Finance & Principal Accounting Officer
No Bio Available

Contacts

Address
TEXAS
Houston
8030 El Rio Street, Parris Building 34, Navy Yard Plaza
Contacts
+13463554099.0
alaunos.com